Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of SIRT-Y90 Followed by Atezolizumab + Bevacizumab vs SIRT-Y90 Followed by Placebo in Locally Advanced Hepatocellular Carcinoma
KCT0009131Phase 2Not yet recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by National Cancer Centre Singapore. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0009131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009131.